March 2019

COVER

SPECIAL FEATURE - Improving Bioavailability & Solubility: Chemical & Physical Modification vs. Formulation Development

Contributor Cindy H. Dubin speaks with several leading companies to explore chemical and physical modification versus formulation development, and new technologies and techniques for improving bioavailability and solubility.

FEATURES

SPECIAL FEATURE - Improving Bioavailability & Solubility: Chemical & Physical Modification vs. Formulation Development

Contributor Cindy H. Dubin speaks with several leading companies to explore chemical and physical modification versus formulation development, and new technologies and techniques for improving bioavailability and solubility.

PRODRUG TECHNOLOGY - Prodrugs for ADHD Treatments: Opportunities & Potential to Fill Unmet Medical Needs

Travis Mickle, PhD, indicates key properties that prodrugs can potentially modify generally fall within one or more of the ADME categories, with the goal being the creation of an NCE that optimizes the performance, utility, and potential life-cycle management of the parent drug.

RNA EDITING - New Editing Technology Enables Body to Repair its Own RNA

Daniel de Boer explains how the Axiomer technology, a powerful RNA-editing technique that enables the body to repair itself, is being developed as a next-generation therapeutic option for genetic disorders.

GLOBAL REPORT - 2018 Global Drug Delivery & Formulation Report: Part 1, a Global Review

In part 1 of this 4-part series, PharmaCircle, in collaboration with Drug Development & Delivery, focuses on a global review of 2018 product approvals.

DRUG DISCOVERY - Validated Phenotypic Approach to Neuropsychiatric Drug Discovery

Emer Leahy, PhD, reviews how the SmartCube platform represents a novel approach to discovering the next generation of breakthrough treatments for schizophrenia and other neuropsychiatric disorders.

ARTIFICIAL INTELLIGENCE - Practical Applications of Artificial Intelligence (AI) for Drug Data Quality & Research

Robert Stanley believes by treating AI as one more tool within a broad data quality toolkit, and by focusing narrowly on specific research and business bottlenecks, it is possible to efficiently bring real practical benefits to research and business.

MULTIPARTICULATE FORMULATIONS - Using Multiparticulate Technology to Develop Pediatric Drug Products

Sven Stegemann, PhD, Matt Shaffer, Samantha Saville, and Jaspreet Arora, PhD, believe as pediatric formulations are expected to continue as a core research area in pharmaceutical technology, MP technologies have the potential to play a key role.

NANOPARTICLE DELIVERY - Ultra-Small Particles Offer Big Hope in Cancer Theranostics

Kai Ma, PhD, Ulrich Wiesner, and Michelle Bradbury, MD, PhD, believe ultra-small sub-10 nm particles hold unique properties and represent an emerging area of investigation for biomedical applications.

EXECUTIVE INTERVIEW - SK life science: Challenges of Developing Therapies for Neurological Diseases

Sebby Borriello, Vice President & Chief Commercial Officer, speaks about the challenges and trends surrounding development of therapies for neurological diseases.

FORMULATION FORUM - Formulation Research Strategy for Discovery-Stage New Drug Candidates

Jim Huang, PhD, and Edward Orton, PhD, say it is critically important CROs or CDMOs that support discovery and preclinical research have the requisite preformulation, formulation, and biopharmaceutics expertise as well as the proprietary methodologies to develop formulations from small quantities of drug candidates for different routes of administration.

CHARACTERIZATION CORNER - From Dilute Sample to Clinically Representative Formulation: Analyzing the Higher Order Structure of mAbs Over a Wide Dynamic Range

Jeff Zonderman explains how the characterization of mAbs at high concentration in clinically representative formulations, without the need for dilution or concern for interference from a formulation buffer’s excipient, is vital.